The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Psoriasis — Biologic Therapy Management (Treatment Selection and Switching)

Comprehensive approach to selecting, initiating, monitoring, and switching biologic therapies in moderate-to-severe psoriasis based on disease subtype (plaque, guttate, pustular, erythrodermic), comorbidities (psoriatic arthritis, IBD, MS, malignancy), prior treatments, and patient preference; covers TNF inhibitors (adalimumab, etanercept, infliximab, certolizumab), IL-17 antagonists (secukinumab, ixekizumab, brodalumab, bimekizumab), IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab), and IL-12/23 inhibitor (ustekinumab) with PASI 90/100 outcomes, screening, and treat-to-target strategies.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dermatoloji department. Book Appointment →

What is Psoriasis — Biologic Therapy Management (Treatment Selection and Switching)?

Biologic therapy comprises monoclonal antibodies and fusion proteins targeting key cytokines or cytokine receptors in psoriasis pathogenesis. Modern biologics revolutionized moderate-to-severe psoriasis treatment, offering: PASI 90 (90 percent improvement) response rates 60–90 percent depending on agent and population, PASI 100 (complete clearance) 30–60 percent, dramatic improvement in dermatology life quality index (DLQI), and resolution of comorbid psoriatic arthritis. Treatment goals shifted from PASI 75 to PASI 90 or PASI 100 (treat-to-target strategy).

Eligibility for biologic therapy generally requires: moderate-to-severe psoriasis (Body Surface Area BSA ≥10 percent, PASI ≥10, or DLQI ≥10), failure or intolerance of or contraindication to phototherapy (NB-UVB) and/or conventional systemic therapy (methotrexate, cyclosporine, acitretin), or special populations (psoriatic arthritis with significant impairment, recalcitrant scalp/palmoplantar/genital psoriasis with major quality of life impact, erythrodermic or generalized pustular psoriasis).

Five major drug classes by target: (1) TNF-α inhibitors (adalimumab, etanercept, infliximab, certolizumab pegol) — first generation, broad activity, well-established long-term safety, important PsA option, but higher infectious risk (TB, hepatitis B reactivation), demyelinating risk, heart failure caution; (2) IL-17 antagonists (secukinumab, ixekizumab anti-IL-17A; brodalumab anti-IL-17 receptor; bimekizumab anti-IL-17A and IL-17F) — rapid and deep skin clearance, excellent for PsA including axial disease, but candida overgrowth risk, exacerbation of IBD (avoid); (3) IL-23p19 inhibitors (guselkumab, risankizumab, tildrakizumab) — newest class, extremely safe with longest dosing intervals (every 8–12 weeks), excellent durability, growing evidence in PsA, suitable in many comorbidities; (4) IL-12/23 inhibitor (ustekinumab anti-p40 subunit shared by IL-12 and IL-23) — long-established safety, dosed every 12 weeks, suitable in many comorbidities including IBD; (5) Newer: tapinarof (topical AhR modulator, FDA approved for plaque psoriasis), oral small molecule deucravacitinib (TYK2 inhibitor — alternative to biologics).

Treatment selection algorithm considerations: (1) Disease subtype — plaque (any biologic), guttate (often resolves spontaneously, biologics rarely needed), pustular and erythrodermic (anti-IL-23, ustekinumab, IL-17, infliximab; spesolimab for generalized pustular psoriasis flares); (2) Psoriatic arthritis — all biologics with PsA indication (TNF, IL-17, IL-12/23, guselkumab, risankizumab); (3) Comorbidities — TNF caution in heart failure (NYHA III-IV), MS or demyelinating disease, latent or active hepatitis B, recurrent infections; IL-17 caution in IBD (Crohn disease, ulcerative colitis — exacerbation risk), candida susceptibility; IL-23 inhibitors with no specific contraindication except pregnancy (preferred in patients with comorbidities); (4) Patient preference for dosing frequency (IL-23 inhibitors every 8–12 weeks favorable for compliance); (5) Cost and access; (6) Pregnancy and lactation (certolizumab pegol preferred in pregnancy due to no active placental transport).

Symptoms

Persistent moderate-to-severe psoriasis (PASI ≥10, BSA ≥10 percent, DLQI ≥10)
Failure of phototherapy and conventional systemic therapy
Significant impact on quality of life despite topical therapy
Concurrent psoriatic arthritis with joint pain and stiffness
Recalcitrant scalp, nail, palmoplantar, or genital psoriasis
Erythrodermic psoriasis (>90 percent BSA erythema and scaling)
Generalized pustular psoriasis with systemic symptoms
Acute or chronic plaque-type psoriasis covering large body areas
Loss of response or adverse events on current biologic — switching consideration
Comorbid IBD (avoid IL-17), MS (avoid TNF), hepatitis B (TNF caution)

Risk Factors

Latent or active tuberculosis (mandatory screening before biologic initiation)
Hepatitis B (active or latent — risk of reactivation with TNF, IL-17, less with IL-23)
Hepatitis C, HIV (manageable with appropriate co-management)
Recurrent serious infections or sepsis history
Active malignancy or recent malignancy (case-by-case assessment)
Heart failure NYHA III-IV (TNF contraindication)
Multiple sclerosis or demyelinating disease (TNF avoidance)
Inflammatory bowel disease (avoid IL-17 antagonists)
Pregnancy and breastfeeding (certolizumab preferred in pregnancy)
Live vaccine requirement (must complete before biologic initiation; avoid during therapy)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Moderate-to-severe psoriasis not controlled with topical or conventional systemic therapy
  • Need for assessment of biologic candidacy and comorbidity screening
  • Psoriatic arthritis with joint damage progression — rheumatology and dermatology coordination
  • Erythrodermic or generalized pustular psoriasis flare — emergent
  • Loss of response on current biologic after initial improvement (secondary failure)
  • Adverse event on biologic (infection, infusion reaction, paradoxical psoriasis)
  • Pregnancy planning while on biologic therapy
  • New comorbidity development (IBD, MS, malignancy, heart failure)
  • Annual TB screening, hepatitis monitoring, vaccination updates
  • Treatment failure assessment and switching decisions

Treatment Methods

01
Pre-biologic mandatory screening: detailed history (infection, malignancy, demyelinating, IBD, family history, travel, immunization status, pregnancy planning), comprehensive physical examination, complete blood count with differential, comprehensive metabolic panel including liver and kidney function, fasting lipid profile, hepatitis B serology (HBsAg, anti-HBc, anti-HBs), hepatitis C antibody, HIV (selected patients per risk), QuantiFERON-TB Gold or TB skin test plus chest X-ray, pregnancy test (women of childbearing potential), age-appropriate cancer screening (Pap smear, mammography, colonoscopy, skin cancer screening), TST every 12 months on therapy
02
Vaccinations: complete all live vaccines >4 weeks before biologic initiation (MMR, varicella if seronegative, yellow fever if travel), inactivated vaccines should be updated (Tdap, influenza annually, COVID-19, pneumococcal PCV13/PPSV23 series, HPV in eligible age group); avoid live vaccines while on biologic
03
Treatment selection guided by disease subtype, comorbidities, severity, prior treatment, dosing preference, cost, and access; first-line biologic options for moderate-to-severe plaque psoriasis include any IL-23 inhibitor (guselkumab, risankizumab, tildrakizumab — excellent safety, long dosing intervals), IL-17 antagonist (secukinumab, ixekizumab, bimekizumab — rapid, deep clearance), or IL-12/23 inhibitor (ustekinumab — long safety record); TNF inhibitors second or third line in current era due to less favorable benefit-risk in plaque-only disease (still excellent option for PsA)
04
Initiation and dosing: follow drug-specific induction and maintenance schedules; counsel on injection technique (most are subcutaneous self-administration), storage (refrigeration required for most), traveling considerations, sharps disposal, side effect awareness; first dose may be administered in clinic for some agents to monitor for hypersensitivity
05
Treat-to-target framework: target PASI 90 at week 16, PASI 100 at 6 months; if PASI 75 or less at week 16, consider dose escalation, switch agent, or address adherence; document baseline PASI, BSA, DLQI, and follow at weeks 4, 12, 16, then every 12 weeks; biomarkers like CRP for systemic inflammation and joint disease
06
Monitoring on therapy: clinical assessment every 3–6 months for skin, joint, comorbidity status; CBC, comprehensive metabolic panel, liver function, lipids every 6–12 months; annual TB screening (TST/IGRA); hepatitis monitoring per baseline status; pregnancy testing when applicable; cancer screening per age guidelines; document and address adverse events
07
Switching biologics: indications include primary non-response (no benefit after adequate trial 12–16 weeks), secondary loss of response (initial improvement followed by relapse), adverse events, comorbidity development; switching strategies — within-class switch (e.g., TNF to TNF — less effective than across class), across-class switch (often more effective), no washout typically needed (start new agent at next planned dose); document reason for switch in record
08
Special populations: pregnancy — certolizumab pegol preferred (no active placental transport via FcRn); other TNF inhibitors and IL-17, IL-23 inhibitors may be considered with risk-benefit discussion; IL-12/23 inhibitors limited pregnancy data; conventional therapies (methotrexate, acitretin contraindicated; cyclosporine acceptable); breastfeeding — generally compatible based on minimal transfer in milk; pediatric — etanercept, ustekinumab, ixekizumab, secukinumab approved for pediatric psoriasis
09
Psoriatic arthritis (PsA): rheumatology coordination essential; biologics with PsA indication preferred (TNF, IL-17, IL-12/23, guselkumab, risankizumab); enthesitis, dactylitis, axial disease assessment; treat-to-target with DAPSA or similar; consider methotrexate adjunct if peripheral arthritis predominant
10
Comorbidity management: cardiovascular risk reduction (psoriasis associated with metabolic syndrome, diabetes, dyslipidemia, atherosclerosis), screening for and treatment of comorbidities; weight loss for obesity-related psoriasis flares; smoking cessation; alcohol moderation; mental health screening (depression, anxiety, suicide ideation prevalent in psoriasis)
11
Long-term: indefinite continued therapy in most patients to maintain remission; periodic reassessment of need; consider tapering or discontinuation in select patients with sustained PASI 100 (controversial); patient education on infection signs, when to hold therapy (active infection, surgery), travel and vaccine considerations; multidisciplinary care (dermatology, rheumatology, primary care, gastroenterology, cardiology, mental health) for complex patients

Which Department to Visit?

You can visit our Dermatoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dermatoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Eczema (Atopic Dermatitis)

Dermatoloji

Atopic dermatitis is a chronic skin disease commonly seen especially in children, flaring with genetic predisposition and environmental triggers.

Psoriasis

Dermatoloji

Psoriasis is an autoimmune disease in which skin cells proliferate rapidly when the immune system mistakenly attacks the skin, leading to thick scaly lesions.

Acne

Dermatoloji

Acne is a skin disease resulting from clogging of hair follicles with oil and dead skin cells, commonly seen in adolescence but can occur at any age.

Rosacea

Dermatoloji

Rosacea is a chronic inflammatory facial skin disease characterized by recurrent flushing, persistent erythema, telangiectasia, and inflammatory papules and pustules. Phymatous change and ocular involvement may complicate advanced disease.

Urticaria (Hives)

Dermatoloji

Urticaria is a skin condition with sudden pink-red wheals and intense itching that may follow an acute or chronic course.

Skin Fungal Infections

Dermatoloji

Skin fungal infections are common, contagious skin diseases caused by dermatophytes and yeast fungi colonizing the upper layers of the skin.

Hair Loss (Alopecia)

Dermatoloji

Alopecia is a general term for hair loss that can be genetic, hormonal, autoimmune, or nutritional; early intervention can slow progression.

Vitiligo

Dermatoloji

Vitiligo is an acquired autoimmune disease in which CD8+ T cells destroy melanocytes, producing well-demarcated depigmented patches. Early, sustained treatment can induce repigmentation and prevent progression; psychosocial impact warrants holistic care.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.